Boston CBS article
Recor Medical Announces U.S. Launch and First Commercial Cases of Paradise Ultrasound Renal Denervation Therapy
Innovative new treatment option for patients with uncontrolled hypertension now available in the United States PALO ALTO, Calif. — Nov. 10, 2023 — Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices
Recor Medical and Otsuka Medical Devices Announce First FDA-Approved Renal Denervation System for the Treatment of Hypertension
Approval of the Paradise™ Ultrasound Renal Denervation system makes innovative hypertension treatment available for the first time in the U.S. Palo Alto, Calif. – November 7, 2023 – Recor Medical, Inc. (“Recor”) and its parent company, Otsuka
Recor Medical Announces Positive Results from Six-Month Pooled Analysis of Data from the RADIANCE Global Clinical Trial Program at TCT 2023
Analysis shows a maintained blood pressure lowering effect with fewer added medications following treatment with the Paradise Ultrasound Renal Denervation system Palo Alto, Calif. – October 26, 2023 – Recor Medical, Inc. (“Recor”) and its parent company,
Recor Medical to Present Latest Clinical Data on Paradise® Ultrasound Renal Denervation at TCT Annual Meeting
Presentations include late-breaking results of six-month pooled analysis of data from the RADIANCE™ Global Clinical Trial Program Palo Alto, Calif. – October 20, 2023 – Recor Medical, Inc. (“Recor”), a subsidiary of Otsuka Medical Devices Co.,
ReCor Responds to European Society of Hypertension’s (ESH) Updated Guidelines for Management of Arterial Hypertension
The new guidelines are designed to serve as a resource on the latest scientific evidence for healthcare professionals around the world who treat people with hypertension.
ReCor Medical Announces Two Concurrent JAMA Network Publications of Study Results on the Paradise Ultrasound Renal Denervation System for the Treatment of Hypertension
Study results showed that the Paradise Ultrasound Renal Denervation (uRDN) System successfully reduced blood pressure compared to sham.
Ms. Barghout brings more than 20 years of experience leading global businesses in the medical device industry.
ReCor Medical and Otsuka Medical Devices Announce Submission of Application for Pre-Market Approval of the Paradise™ Ultrasound Renal Denervation (uRDN) System to the U.S. Food and Drug Administration
The Paradise uRDN System is designed to reduce sympathetic nerve activity by denervating nerves which surround the renal arteries with the goal of reducing blood pressure.
ReCor Medical Announces Consistent Reduction of Blood Pressure in Pooled Analysis of Three Clinical Trials at AHA 2022
The results come from analysis of the pooled data from ReCor’s RADIANCE Global Clinical Trial Program.